In November last year, the Biden administration proposed a new rule that would allow drugs like Wegovy and Zepbound to be covered by Medicare and Medicaid, expanding access for roughly 3.4 million Medicare users and about 4 million Medicaid enrollees.

Proponents of coverage argued treating obesity can reduce longer-term costs by cutting down on heart attacks and other health complications.